uniQure (QURE) to Release Earnings on Tuesday

uniQure (NASDAQ:QURE - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect uniQure to post earnings of ($1.07) per share for the quarter.

uniQure Price Performance

Shares of uniQure stock opened at $14.12 on Tuesday. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business's 50-day moving average price is $11.95 and its 200-day moving average price is $11.68. The firm has a market capitalization of $763.57 million, a PE ratio of -2.87 and a beta of 0.42.

Wall Street Analysts Forecast Growth

Several research firms recently commented on QURE. StockNews.com raised shares of uniQure to a "sell" rating in a report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of uniQure in a research note on Monday, April 21st. Wells Fargo & Company reduced their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. Chardan Capital initiated coverage on uniQure in a research report on Tuesday, April 1st. They issued a "buy" rating and a $38.00 price objective for the company. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $38.80.

Insider Buying and Selling at uniQure

In other news, CFO Christian Klemt sold 14,341 shares of the company's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $153,448.70. Following the transaction, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares of the company's stock, valued at $6,574,599.40. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,830 shares of company stock valued at $961,401. Company insiders own 4.74% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.